Table 3.

Clinico-pathological parameters and known driver mutations in relation to ARID1A expression loss.

		ARID1A Expression b
		n a	0–2	3–12	p-Value c
Parameter:
Age at diagnosis
	median age: 67 years
	≤67 years	56	3	53	0.954
	>67 years	53	3	50
Gender
	female	55	3	52	0.963
	male	53	3	50
Histological tumor grade d
	G1-G2	30	2	28	0.816
	G3	73	4	69
Tumor stage d
	pT1-pT2	13	0	13	0.328
	pT3-pT4	86	6	80
Lymph node status
	neg	65	4	61	0.600
	neg	21	2	19
TP53 mut e
	neg	30	0	30	0.030
	neg	27	4	23
FGFR3 mut e
	neg	50	4	46	0.442
	neg	7	0	7
CDKNA2 mut e
	neg	51	4	47	0.520
	neg	5	0	5
PIK3CA mut e
	neg	45	4	41	0.288
	pos	12	0	12

^a Only patients with primary bladder cancer were included: ^b IRS according to Remmele [35]; ^c Fisher’s exact test; ^d according to WHO 2004 classification; ^e due to limited availability of material, experimental data, case numbers vary for different methods as indicated. Significant p-values are marked in bold face.